Published in Nat Rev Urol on May 24, 2016
HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors | NCT00931931
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer (BOND) | NCT01438112
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors | NCT00625456
PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer | NCT00005916
Mechanism of Action Trial of ColoAd1 (MOA) | NCT02053220
Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers | NCT00636558
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A (1993) 11.95
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39
Renal-cell carcinoma. N Engl J Med (2005) 10.17
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Functions of natural killer cells. Nat Immunol (2008) 9.88
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res (2014) 8.11
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 5.97
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 5.89
Oncolytic virotherapy. Nat Biotechnol (2012) 5.79
Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature (2005) 5.32
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31
Integrative clinical genomics of advanced prostate cancer. Cell (2015) 5.29
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med (2013) 4.86
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol (2015) 4.85
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med (2000) 4.37
Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature (1992) 4.36
Reovirus therapy of tumors with activated Ras pathway. Science (1998) 4.15
Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A (1998) 3.89
A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A (2008) 3.83
Engineering targeted viral vectors for gene therapy. Nat Rev Genet (2007) 3.69
Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol (2006) 3.46
Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol (2007) 3.37
Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res (1997) 3.37
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A (1996) 3.29
Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science (1997) 2.92
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med (2014) 2.82
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet (2009) 2.76
Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog (2011) 2.74
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A (2006) 2.72
A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology (2000) 2.69
Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst (2007) 2.59
History of oncolytic viruses: genesis to genetic engineering. Mol Ther (2007) 2.51
Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Semin Immunol (1998) 2.51
Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med (2004) 2.42
NK cells and cancer immunosurveillance. Oncogene (2008) 2.34
HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res (2000) 2.25
Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys (2014) 2.21
DNA repair proteins affect the lifecycle of herpes simplex virus 1. Proc Natl Acad Sci U S A (2005) 2.20
Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res (2002) 2.19
A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res (2008) 2.18
Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med (2007) 2.15
History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol (2007) 2.15
The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther (2009) 2.14
Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther (2007) 2.14
High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res (2004) 2.14
The mutational landscape of prostate cancer. Eur Urol (2013) 2.14
Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J Virol (2003) 2.10
Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell (2004) 2.05
Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci U S A (2000) 1.99
FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One (2010) 1.97
Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res (2006) 1.94
Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther (2007) 1.93
Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther (2006) 1.88
Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry. J Virol (1997) 1.88
MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells. Clin Cancer Res (2009) 1.82
Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life (2000) 1.81
Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res (1997) 1.79
A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol (2012) 1.75
Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract (2011) 1.75
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther (2006) 1.74
Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells (2008) 1.74
A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol (2015) 1.73
Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol (2004) 1.72
Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol Ther (2009) 1.72
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs (2009) 1.71
Intelligent design: combination therapy with oncolytic viruses. Mol Ther (2009) 1.68
A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res (2001) 1.68
The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer. Clin Cancer Res (2015) 1.68
Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clin Cancer Res (2010) 1.63
Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity. Blood (2013) 1.61
Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res (2001) 1.61
The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther (2011) 1.59
Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther (2008) 1.59
Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res (2003) 1.59
Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer (2000) 1.58
Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer. Mol Ther (2012) 1.57
Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus. Cancer Res (2008) 1.57
Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res (2013) 1.55
Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res (2000) 1.55
Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res (2002) 1.55
PSA/KLK3 AREI promoter polymorphism alters androgen receptor binding and is associated with prostate cancer susceptibility. Carcinogenesis (2006) 1.53
PD-1/PD-L1 inhibitors. Curr Opin Pharmacol (2015) 1.53
REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res (2010) 1.53
Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol (2005) 1.50
Directing cell therapy to anatomic target sites in vivo with magnetic resonance targeting. Nat Commun (2015) 1.50
Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther (2002) 1.49
Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst (2006) 1.47
Binding of the Rb1 protein to E1A products is required for adenovirus transformation. Oncogene (1989) 1.47
Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther (2007) 1.46
Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Transl Med (2012) 1.46
Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int (2012) 1.46
Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder. Urol Oncol (2015) 1.45